Combining Notch and ErbB-2 Inhibitors to Prevent Breast Tumour Recurrence
Author Information
Author(s): Pandya K, Meeke K, Clementz A G, Rogowski A, Roberts J, Miele L, Albain K S, Osipo C
Primary Institution: Loyola University Chicago
Hypothesis
Can combining a Notch inhibitor with trastuzumab prevent recurrence of ErbB-2-positive breast tumours?
Conclusion
Combining Notch and ErbB-2 inhibitors significantly reduces recurrence rates in ErbB-2-positive breast tumours.
Supporting Evidence
- Trastuzumab treatment alone led to 40% recurrence in mice.
- Combining trastuzumab with MRK-003 GSI resulted in 0% recurrence.
- Notch inhibition delayed tumour regrowth significantly.
- Combination therapy reduced tumour size compared to single treatments.
Takeaway
This study shows that using two types of medicine together can help stop breast cancer from coming back.
Methodology
The study used orthotopic breast tumour xenografts in mice to test the effects of trastuzumab and Notch inhibitors.
Potential Biases
Potential bias in the selection of treatment groups and outcomes measured.
Limitations
The study was limited to preclinical models and may not fully translate to human patients.
Participant Demographics
Mice used were ovariectomised, athymic nude mice.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website